Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

38.40
+0.59001.56%
Pre-market: 38.01-0.3900-1.02%04:35 EDT
Volume:1.24M
Turnover:47.92M
Market Cap:7.15B
PE:-9.56
High:39.06
Open:38.11
Low:38.11
Close:37.81
Loading ...

Revolution Medicines Initiated at Buy by Goldman Sachs

Dow Jones
·
15 Jul

Revolution Medicines initiated with a Buy at Goldman Sachs

TIPRANKS
·
15 Jul

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

THOMSON REUTERS
·
09 Jul

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

GlobeNewswire
·
09 Jul

Truist biotech analyst holds an analyst/industry conference call

TIPRANKS
·
04 Jul

Revolution Medicines, Summit Therapeutics Partner to Test Cancer Treatment Combinations

MT Newswires Live
·
30 Jun

BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors

Reuters
·
30 Jun

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three Ras(on) Inhibitors With Ivonescimab in Ras Mutant Tumors

THOMSON REUTERS
·
30 Jun

Revolution Medicines Inc - Summit to Supply Ivonescimab, Revolution Medicines to Sponsor Study

THOMSON REUTERS
·
30 Jun

Revolution Medicines Inc. Conducted Annual Stockholder Meeting

Reuters
·
28 Jun

Revolution Medicines Price Target Maintained With a $57.00/Share by Needham

Dow Jones
·
25 Jun

Wedbush Lifts Price Target on Revolution Medicines to $73 From $67, Keeps Outperform Rating

MT Newswires Live
·
25 Jun

Strategic Partnership with Royalty Pharma Enhances Revolution Medicines’ Financial Flexibility and Growth Potential

TIPRANKS
·
25 Jun

Revolution Medicines Shares Down 3.5% After Deal With Royalty Pharma

THOMSON REUTERS
·
24 Jun

Royalty Pharma Plc - to Provide up to $1.25 Bln in Exchange for a Synthetic Royalty on Annual Worldwide Net Sales of Daraxonrasib

THOMSON REUTERS
·
24 Jun

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement With Royalty Pharma to Support Global Development and Commercialization of Ras(on) Inhibitor Portfolio for Patients With Ras-Addicted Cancers

THOMSON REUTERS
·
24 Jun

Revolution Medicines Inc - Term Loan Interest Rate Sofr Plus 5.75%, Principal Due by 2032

THOMSON REUTERS
·
24 Jun

Press Release: Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Dow Jones
·
24 Jun

General Counsel Jeff Cislini Reports Disposal of Revolution Medicines Inc. Common Shares

Reuters
·
24 Jun

BRIEF-Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Reuters
·
23 Jun